High-dose oral ibuprofen in treatment of patent ductus arteriosus in full-term neonates

Iranian Journal of Pediatrics

Volumn 25, Issue 4, 2015, Pages

  Pourarian, Shahnaz ^a   Rezaie, Mehrdad ^a   Amoozgar, Hamid ^a   Shakiba, Ali Mohammad ^a   Edraki, Mohammad Reza ^a   Mehdizadegan, Nima ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ductus arteriosus; High dose oral ibuprofen; Patient; Term neonate

Indexed keywords

IBUPROFEN;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GENDER; GESTATIONAL AGE; HUMAN; IRAN; MALE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PEDIATRIC WARD; UNIVERSITY HOSPITAL;

EID: 84943743004     PISSN: 20082142     EISSN: 20082150     Source Type: Journal    
DOI: 10.5812/ijp.2005     Document Type: Article

References (21)

1. Allen HD, Driscoll DJ, Shaddy RE, Feltes T. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 7 ed. Philadelphia: Lippincott Williams and Wilkins; 2007.
2. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998;50(1):35–58.
3. Thebaud B, Michelakis ED, Wu XC, Moudgil R, Kuzyk M, Dyck JR, et al. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation. 2004;110(11):1372–9.
4. Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med. 2002;8(2):91–2.
5. Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest. 2002;110(4):549–57.
6. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature. 1997;390(6655):78–81.
7. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun.1998;246(1):7–12.
8. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890–900.
9. Mullins CE. Patent ductus arteriosus. In: Garson A, Bricker JT, McNamara DG, editors. The Science and Practice of Pediatric Cardiology. Philadelphia: Lea & Febiger; 1990. p. 1055–6.
10. Milliken JC, D'Souza G. Patent Ductus Arteriosus. Review Article eMedicine cardiology.2007;115(8):1039–50.
11. Madan JC, Kendrick D, Hagadorn JI, Frantz I3, National Institute of Child H, Human Development Neonatal Research N. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.Pediatrics. 2009;123(2):674–81.
12. Benjamin JR, Smith PB, Cotten CM, Jaggers J, Goldstein RF, Malcolm WF. Long-term morbidities associated with vocal cord paralysis after surgical closure of a patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2010;30(6):408–13.
13. Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. Pediatr Cardiol. 2010;31(1):40–3.
14. Timethy M, Hugh D., Allen DJ, Driscoll RES. Physiology of the preterm and term infant. Moss and Adams' Heart Disease in Infants, Children, and Adolescents. 7 ed. Philadelphia: Lippincott Williams and Wilkins; 2008. pp. 440–1.
15. Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J. 1977;39(6):610–8.
16. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics. 1978;62(5):706–12.
17. Watanabe K, Tomita H, Ono Y, Yamada O, Kurosaki K, Echigo S. Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects. Circ J. 2003;67(9):750–2.
18. Takami T, Yoda H, Kawakami T, Yamamura H, Nakanishi T, Nakazawa M, et al. Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol. 2007;28(1):46–50.
19. Rudolph AM. The ductus arteriosus and persistent patency of the ductus arteriosus. In: Rudolph AM, editor. Congenital Disease of The Heart. 2 ed. Armonk, NY: Future; 2001. pp. 155–96.
20. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995;127(3):466–71.
21. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005;164(3):135–40.